Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients

Breast Cancer Research and Treatment

Volumn 119, Issue 2, 2010, Pages 347-356

  Parissenti, Amadeo M ^a   Chapman, Judy Anne W ^b   Kahn, Harriette J ^c   Guo, Baoqing ^a   Han, Lei ^b   O'Brien, Patti ^b   Clemons, Mark P ^d   Jong, Roberta ^c   Dent, Rebecca ^c   Fitzgerald, Barbara ^d   Pritchard, Kathleen I ^c   Shepherd, Lois E ^b   Trudeau, Maureen E ^c  

^a LAURENTIAN UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Biomarker; Breast neoplasms; Cancer treatment; Clinical trial, phase I; Clinical trial, phase II; Docetaxel; Drug response; Epirubicin; RNA integrity

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; HEMATOXYLIN; PROGESTERONE RECEPTOR; RNA;

ALOPECIA; ANOREXIA; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; HEARTBURN; HOT FLUSH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MYALGIA; NAUSEA; PRIORITY JOURNAL; STOMATITIS; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; ELECTROPHORESIS, CAPILLARY; EPIRUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA STABILITY; RNA, NEOPLASM; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 74849085436     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0531-x     Document Type: Article

References (38)

1. JG Zijlstra S de Jong EG de Vries NH Mulder 1990 Topoisomerases, new targets in cancer chemotherapy Med Oncol Tumor Pharmacother 7 1 11 18 1:STN:280:DyaK3c3ltV2ktQ%3D%3D 2160032
2. DS Richardson SA Johnson 1997 Anthracyclines in haematology: preclinical studies, toxicity and delivery systems Blood Rev 11 4 201 223 10.1016/S0268-960X(97)90020-5 1:STN:280:DyaK1c7kt1Cnuw%3D%3D 9481450 (Pubitemid 28045205)
3. G Capranico S Tinelli F Zunino 1989 Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells Chem Biol Interact 72 1-2 113 123 10.1016/0009-2797(89)90022-7 1:CAS:528: DyaK3cXmvFGitQ%3D%3D 2555070
4. M Chazard B Pellae-Cosset F Garet JA Soares B Lucidi Y Lavail, et al. 1994 Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes Bull Cancer 81 3 173 181 1:STN:280:DyaK2M3gtFequg%3D%3D 7894125
5. M Distefano G Scambia C Ferlini C Gaggini R De Vincenzo A Riva, et al. 1997 Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10- deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells Int J Cancer 72 5 844 850 10.1002/(SICI)1097-0215(19970904)72:5<844:: AID-IJC22>3.0.CO;2-7 1:CAS:528:DyaK2sXmtVKku7c%3D 9311603 (Pubitemid 27431529)
6. PJ Moos FA Fitzpatrick 1998 Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis Proc Natl Acad Sci USA 95 7 3896 3901 10.1073/pnas.95.7.3896 1:CAS:528:DyaK1cXitlKjurw%3D 9520464 (Pubitemid 28173225)
7. RS Weinstein JR Kuszak LF Kluskens JS Coon 1990 P-glycoproteins in pathology: the multidrug resistance gene family in humans Hum Pathol 21 1 34 48 10.1016/0046-8177(90)90073-E 1:CAS:528:DyaK3cXktlChsbY%3D 1967244 (Pubitemid 20042403)
8. RS Kerbel H Kobayashi CH Graham 1994 Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 56 1 37 47 10.1002/jcb.240560108 1:CAS:528:DyaK2cXlvFCkt74%3D 7806590
9. RL Juliano V Ling 1976 A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 455 1 152 162 10.1016/0005-2736(76)90160-7 1:CAS:528:DyaE28XlvV2qs70%3D 990323
10. WT Beck TJ Mueller LR Tanzer 1979 Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts Cancer Res 39 6 Pt 1 2070 2076 1:CAS:528:DyaE1MXkvV2itrY%3D 571759
11. SP Cole G Bhardwaj JH Gerlach JE Mackie CE Grant KC Almquist, et al. 1992 Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments] Science 258 5088 1650 1654 10.1126/science.1360704 1:CAS:528:DyaK3sXkvFantLc%3D 1360704
12. AM Fry CM Chresta SM Davies MC Walker AL Harris JA Hartley, et al. 1991 Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines Cancer Res 51 24 6592 6595 1:CAS:528:DyaK38XjsVSqtA%3D%3D 1660343
13. G Giaccone AF Gazdar H Beck F Zunino G Capranico 1992 Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression Cancer Res 52 7 1666 1674 1:CAS:528:DyaK38XitVOntLg%3D 1312895
14. EK Balcer-Kubiczek J Yin K Lin GH Harrison JM Abraham SJ Meltzer 1995 p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons Radiat Res 142 3 256 262 10.2307/3579133 1:CAS:528:DyaK2MXmtFelu7s%3D 7761574
15. T Aas AL Borresen S Geisler B Smith-Sorensen H Johnsen JE Varhaug, et al. 1996 Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nat Med 2 7 811 814 10.1038/nm0796-811 1:CAS:528:DyaK28XjvF2isrY%3D 8673929 (Pubitemid 26225099)
16. G Batist A Tulpule BK Sinha AG Katki CE Myers KH Cowan 1986 Overexpression of a novel anionic glutathione transferase in multidrug- resistant human breast cancer cells J Biol Chem 261 33 15544 15549 1:CAS:528:DyaL28XmtVartbw%3D 3782078
17. G Batist BC Behrens R Makuch TC Hamilton AG Katki KG Louie, et al. 1986 Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro Biochem Pharmacol 35 13 2257 2259 10.1016/0006-2952(86)90601-5 1:CAS:528:DyaL28Xkslaht74%3D 3827990 (Pubitemid 16069284)
18. AL Harris D Hochhauser 1992 Mechanisms of multidrug resistance in cancer treatment Acta Oncol 31 2 205 213 10.3109/02841869209088904 1:STN:280: DyaK38zit1amsQ%3D%3D 1352455
19. F Cabral I Abraham MM Gottesman 1981 Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin Proc Natl Acad Sci USA 78 7 4388 4391 10.1073/pnas.78.7.4388 1:CAS:528: DyaL3MXltV2ntLc%3D 6117076 (Pubitemid 11010207)
20. MJ Schibler B Huang 1991 The colR4 and colR15 beta-tubulin mutations in Chlamydomonas reinhardtii confer altered sensitivities to microtubule inhibitors and herbicides by enhancing microtubule stability J Cell Biol 113 3 605 614 10.1083/jcb.113.3.605 1:CAS:528:DyaK3MXisVCiur4%3D 1673126
21. WA Weber M Schwaiger N Avril 2000 Quantitative assessment of tumor metabolism using FDG-PET imaging Nucl Med Biol 27 7 683 687 10.1016/S0969- 8051(00)00141-4 1:CAS:528:DC%2BD3cXot1ygsro%3D 11091112 (Pubitemid 30847774)
22. SJ Kim SK Kim ES Lee J Ro S Kang 2004 Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy Ann Oncol 15 9 1352 1357 10.1093/annonc/mdh345 15319241 (Pubitemid 39295023)
23. GM McDermott A Welch RT Staff FJ Gilbert L Schweiger SI Semple, et al. 2007 Monitoring primary breast cancer throughout chemotherapy using FDG-PET Breast Cancer Res Treat 102 1 75 84 10.1007/s10549-006-9316-7 1:CAS:528:DC%2BD2sXhslCltrg%3D 16897427 (Pubitemid 46294965)
24. R Kumar A Chauhan H Zhuang P Chandra M Schnall A Alavi 2006 Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer Breast Cancer Res Treat 98 3 267 274 10.1007/s10549-006-9159-2 16555126 (Pubitemid 44195596)
25. N Avril CA Rose M Schelling J Dose W Kuhn S Bense, et al. 2000 Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 20 3495 3502 1:STN:280: DC%2BD3M%2Fhsl2hsA%3D%3D 11032590
26. HS Lim W Yoon TW Chung JK Kim JG Park HK Kang, et al. 2007 FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations Radiographics 27 Suppl 1 S197 S213 10.1148/rg.27si075507 18180227
27. FY de Vos PH Willemse EG de Vries JA Gietema 2004 Endothelial cell effects of cytotoxics: balance between desired and unwanted effects Cancer Treat Rev 30 6 495 513 10.1016/j.ctrv.2004.05.003 15325031 (Pubitemid 39157851)
28. A Schroeder O Mueller S Stocker R Salowsky M Leiber M Gassmann, et al. 2006 The RIN: an RNA integrity number for assigning integrity values to RNA measurements BMC Mol Biol 7 3 10.1186/1471-2199-7-3 16448564
29. S Weis IC Llenos JR Dulay M Elashoff F Martinez-Murillo CL Miller 2007 Quality control for microarray analysis of human brain samples: The impact of postmortem factors, RNA characteristics, and histopathology J Neurosci Methods 165 2 198 209 10.1016/j.jneumeth.2007.06.001 1:CAS:528:DC%2BD2sXovFOjsbo%3D 17628689 (Pubitemid 47212459)
30. C Strand J Enell I Hedenfalk M Ferno 2007 RNA quality in frozen breast cancer samples and the influence on gene expression analysis-a comparison of three evaluation methods using microcapillary electrophoresis traces BMC Mol Biol 8 38 10.1186/1471-2199-8-38 17519006 (Pubitemid 46916153)
31. S Fleige V Walf S Huch C Prgomet J Sehm MW Pfaffl 2006 Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR Biotechnol Lett 28 19 1601 1613 10.1007/s10529-006-9127-2 1:CAS:528:DC%2BD28Xosleqsr8%3D 16900335 (Pubitemid 44306128)
32. GEP Box DR Cox 1964 Analysis of transformations J Roy Stat Soc Ser Bull 26 211 252
33. R Daoust LG De 1975 Ribonucleases and neoplasia Subcell Biochem 4 3 185 211 1:CAS:528:DyaE28XlsVSksLY%3D 183316
34. KL King CM Jewell CD Bortner JA Cidlowski 2000 28S ribosome degradation in lymphoid cell apoptosis: evidence for caspase and Bcl-2-dependent and-independent pathways Cell Death Differ 7 10 994 1001 10.1038/sj.cdd.4400731 1:CAS:528:DC%2BD3cXnslWju78%3D 11279546
35. M Irie 1999 Structure-function relationships of acid ribonucleases: lysosomal, vacuolar, and periplasmic enzymes Pharmacol Ther 81 2 77 89 10.1016/S0163-7258(98)00035-7 1:CAS:528:DyaK1MXovVOntQ%3D%3D 10190580 (Pubitemid 29073557)
36. ME Maragoudakis P Peristeris E Missirlis A Aletras P Andriopoulou G Haralabopoulos 1994 Inhibition of angiogenesis by anthracyclines and titanocene dichloride Ann N Y Acad Sci 732 280 293 10.1111/j.1749-6632.1994.tb24743.x 1:CAS:528:DyaK2MXjvFWqt7k%3D 7526759
37. DS Grant TL Williams M Zahaczewsky AP Dicker 2003 Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int J Cancer 104 1 121 129 10.1002/ijc.10907 1:CAS:528:DC%2BD3sXhtlCgu7c%3D 12532428 (Pubitemid 36184155)
38. XS Zhang XF Zhu JS Gao YL Ye QS Feng ZC Liu, et al. 2002 Variable sensitivity of endothelial cells to epirubicin in xenografts of human nasopharyngeal carcinoma CNE-2 cells Cancer Biol Ther 1 3 263 265 1:CAS:528:DC%2BD3sXlt1Whsg%3D%3D 12432274